

Attorney Docket No. 4189.0083-06000

In re Application of:

Thompson et al.

Application No.: 08/482,283

Filed: June 7, 1995

For: NUCLEIC ACIDS ENCODING  
INTERLEUKIN-1 RECEPTOR  
ANTAGONISTS

Group Art Unit: 1647

Examiner: L. Spector

RECEIVED

MAR 23 2007

TECH CENTER 1600/2900

02 MAR 21 PM 2:51

RECEIVED  
FBI CENTER 1600/2300

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Office Action after the Request for Examination After Final Under 37 C.F.R. §1.129(a) was filed December 3, 2001, a Quayle Action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Applicants enclose copies of the documents listed on the attached Form PTO

1449. Applicants respectfully request that the Examiner consider the listed documents

03/22/2002 TSUGGS

01 FC:126

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

and indicate that they were considered by making appropriate notations on the attached form.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Please grant any extensions of time required to enter this Information Disclosure Statement and charge any additional fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By: 

M. Paul Barker  
Reg. No. 32,013

Dated: March 20, 2002

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com